Innoviva reported Q4 2025 total revenue of USD 114.6 million (+25%) and FY 2025 total revenue of USD 411.3 million (+15%). Q4 2025 net income was USD 164.2 million and FY 2025 net income was USD 271.2 million; Q4 basic EPS was USD 2.19 and FY basic EPS was USD 4.02. Q4 2025 gross royalty revenue from GSK was USD 58.4 million and FY 2025 was USD 250.3 million. Q4 2025 net product sales were USD 59.1 million (more than doubled) and FY 2025 net product sales were USD 172.1 million (+77%), including IST U.S. net product sales of USD 33.9 million in Q4 and USD 119.2 million in FY (+47%). Cash and cash equivalents were USD 550.9 million as of Dec. 31, 2025. For business updates, Innoviva said the U.S. FDA approved NUZOLVENCE (zoliflodacin) in December 2025 for uncomplicated urogenital gonorrhea, with commercialization planned for H2 2026. The company highlighted the mid-2025 U.S. launch of ZEVTERA and noted ZEVTERA and XACDURO were nominated for the 2025 Prix Galien USA Award. Innoviva also initiated a USD 125 million share repurchase program and said it has repurchased 797,298 shares for USD 16.0 million to date, and it invested USD 17.5 million in Beacon Biosignals’ Series B preferred stock.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innoviva Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602251605BIZWIRE_USPR_____20260225_BW055287) on February 25, 2026, and is solely responsible for the information contained therein.
Comments